News & Updates

Patients with Alagille syndrome (AS) may benefit from treatment with odevixibat, with the phase III ASSERT study showing that its use results in rapid, sustained, and highly significant improvements in pruritus, sleep quality, as well as decreases in bile acids (BAs). Odevixibat is also well tolerated.

New drug applications approved by US FDA as of 01-15 June 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Use of teduglutide is effective against short bowel syndrome (SBS) in paediatric patients, although some children need a longer duration of treatment to achieve enteral autonomy, according to a Spain study presented at ESPGHAN 2023. Predictive factors of response to treatment have not been identified.

Treatment with dupilumab significantly improves histologic and endoscopic measures of eosinophilic esophagitis (EoE) in young children aged 1–11 years, according to the phase III EoE KIDS trial presented at ESPGHAN 2023.

An elevated proportion of children and adolescents around the world, particularly girls or those with high BMI, experience disordered eating as shown in a meta-analysis of 32 studies from 16 countries.

A case-control surveillance study has found no link between monovalent COVID-19 boosters and miscarriage before 20 weeks of pregnancy.

Adding the probiotic Limosilactobacillus reuteri (L. reuteri) DSM 17938 to antibiotic therapy significantly reduced the incidence of antibiotic-associated diarrhoea (AAD) in children with acute otitis media or acute bacterial sinusitis in the PEARL study presented at ESPGHAN 2023.